| --- | --- | |-----------------|-------| | | | | | | | | | | Ironwood 2Q | 2021 | | | | | | | | Earnings Update | | | August 5, 2021 | | Ironwood Introduction Matt Roache Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision and mission; our strategy, business, financial position and operations, including with respect to maximizing L ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q2 2021 Earnings Conference Call August 5, 2021 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Jason Rickard - Chief Operating Officer Mike Shetzline - Chief Medical Officer Conference Call Participants Hannah Adeoye - JPMorgan Avatar Jones - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Ironwood Pharmaceuticals 2Q 2021 Investor Update Call. At this time, all par ...

| --- | --- | |------------------|-------| | | | | | | | | | | Ironwood 1Q 2021 | | | | | | Earnings Update | | Ironwood Introduction Meredith Kaya Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision and mission; our strategy, business, financial position and operations, including with respect to maximizing LINZESS® (linaclotide), b ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q1 2021 Earnings Conference Call May 6, 2021 8:30 AM ET Company Participants Meredith Kaya - VP, IR & Corporate Communications Thomas McCourt - President & Interim CEO Gina Consylman - Principal Accounting Officer, CFO, SVP & Treasurer Michael Shetzline - Chief Medical Officer, SVP & Head, Drug Development Conference Call Participants Jacob Hughes - Wells Fargo Securities Hannah Adeoye - JPMorgan Chase & Co. David Lebowitz - Morgan Stanley Operator Good day, and ...

| --- | --- | --- | |-------------------------|-------|-------| | | | | | Ironwood 4Q and FY 2020 | | | Ironwood Introduction Meredith Kaya Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision and mission; the Company's strategy, business, financial position and operations, including with respect to maximizing LINZESS® (linaclotide), ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2020 Earnings Conference Call February 17, 2021 8:30 AM ET Company Participants Meredith Kaya - VP, IR and Corporate Communications Mark Mallon - CEO Thomas McCourt - President Gina Consylman - SVP and CFO Michael Shetzline - CMO, SVP and Head of Drug Development Conference Call Participants Unidentified Analyst - Credit Suisse Eric Joseph - J.P. Morgan Boris Peaker - Cowen and Company Jacob Hughes - Wells Fargo Operator Ladies and gentlemen, thank you for sta ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2020 Results Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Meredith Kaya - Vice President, Investor Relations and Corporate Communications Mark Mallon - Chief Executive Officer Mark Plinio - Chief Commercial Officer Gina Consylman - Chief Financial Officer Mike Shetzline - Chief Medical Officer Conference Call Participants David Lebowitz - Morgan Stanley Eric Joseph - JP Morgan Tim Chiang - Northland Securities Operator Ladies and g ...

| --- | --- | --- | --- | --- | |-----------------------------------|-------|-------|-------|-------| | | | | | | | Ironwood 3Q 2020 Investor Update | | | | | | November 5, 2020 | | | | | | | | | | | | | | | | | | | | | | | Introduction Meredith Kaya Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision to become a leader in GI; our a ...